Poliomyelitis

Pipeline Programs

Companies

Clinical Trials

6 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine

18100%

+ 38 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Sinovac BiotechChina - Beijing

14 programs

2wIPV+1sIPVPhase 41 trial

sIPVPhase 41 trial

sIPV vaccine /DTaP vaccinePhase 4Vaccine1 trial

+9 more programs

Active Trials

NCT04989231Completed450Est. Dec 2022

NCT04618783Completed250Est. Jan 2020

NCT02985320Completed708Est. Jun 2017

+11 more trials

ViiV HealthcareNC - Durham

12 programs

Boostrix-PolioPhase 4

Infanrix™ pentaPhase 4

Poliorix TMPhase 4

Infanrix hexaPhase 3

Infanrix hexa™Phase 3

+7 more programs

AJ VaccinesDenmark - Copenhagen

5 programs

IPV-AlPhase 41 trial

Inactivated Polio Vaccine, adjuvanted reduced dosePhase 4Vaccine

IPV-Al SSIPhase 31 trial

Active Trials

NCT03032419Completed1,002Est. Mar 2018

NCT03025750Completed800Est. Nov 2017

NCT03671616Completed666Est. Oct 2018

+1 more trials

BiocorpFrance - Issoire

6 programs

BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 1Phase 3Vaccine1 trial

Novel Live Attenuated Type 1 Oral Poliomyelitis VaccinePhase 2Vaccine1 trial

Novel Live Attenuated Type 3 Oral Poliomyelitis VaccinePhase 2Vaccine1 trial

Novel Oral Polio Vaccine Type 1Phase 2Vaccine1 trial

novel oral polio type 2 vaccinePhase 2Vaccine1 trial

+1 more programs

Active Trials

NCT06137664Recruiting2,400Est. Dec 2027

NCT05644184Recruiting2,232Est. May 2026

NCT05654467Unknown1,532Est. Nov 2025

+3 more trials

Syneos HealthNC - Morrisville

1 program

IPV-Al SSIPhase 3

CanSino BiologicsChina - Tianjin

2 programs

Recombinant Trivalent Poliomyelitis VaccinePhase 1/2Vaccine1 trial

Recombinant Trivalent Poliomyelitis VaccinePhase 1Vaccine1 trial

Active Trials

NCT06101173Completed72Est. Sep 2024

NCT06577298Recruiting480Est. Dec 2026

GSKLONDON, United Kingdom

12 programs

Poliomyelitis vaccineN/AVaccine1 trial

PoliorixPHASE_11 trial

Infanrix hexaPHASE_31 trial

Infanrix hexa™PHASE_31 trial

Infanrix™-IPV+HibPHASE_31 trial

+7 more programs

Active Trials

NCT00514033Completed349Est. Jul 2011

NCT00937404Completed25Est. Nov 2009

NCT02096263Completed585Est. Nov 2015

+9 more trials

SanofiPARIS, France

4 programs

Inactivated Poliomyelitis vaccinePHASE_3Vaccine2 trials

Poliomyelitis Vaccine inactivatedPHASE_3Vaccine1 trial

IMOVAX POLIO®: Inactive Poliovirus VaccinePHASE_4Vaccine1 trial

IMOVAX Polio™-Inactivated types 1, 2, and 3 poliovirus D vaccinePHASE_4Vaccine1 trial

Active Trials

NCT00604058Completed236Est. Dec 2008

NCT00258843Completed40Est. Apr 2006

NCT00348387Completed600Est. Dec 2008

+2 more trials

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

Sinovac Biotech2wIPV+1sIPV

Sinovac BiotechsIPV

Sinovac BiotechsIPV vaccine /DTaP vaccine

AJ VaccinesIPV-Al

SanofiIMOVAX POLIO®: Inactive Poliovirus Vaccine

GSKPoliorix TM

SanofiIMOVAX Polio™-Inactivated types 1, 2, and 3 poliovirus D vaccine

GSKInfanrix™ penta

GSKBoostrix-Polio

Sinovac BiotechSabin Strain Inactivated Poliovirus Vaccine

Sinovac BiotechExperimental vaccine

Sinovac BiotechThree doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age

Sinovac BiotechsIPV-sIPV-bOPV vaccination schedule

Showing 15 of 43 trials with date data

Clinical Trials (43)

Total enrollment: 30,488 patients across 43 trials

NCT07457060 Sinovac Biotech2wIPV+1sIPV

Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine

Start: Nov 2025Est. completion: Oct 2026480 patients

Phase 4Recruiting

NCT07354269 Sinovac BiotechsIPV

Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations

Start: Sep 2025Est. completion: May 2026180 patients

Phase 4Recruiting

NCT06442449 Sinovac BiotechsIPV

Booster Dose of sIPV Co-administered With MMR and HepA-I.

Start: Aug 2024Est. completion: Oct 2025889 patients

Phase 4Completed

NCT06346834 Sinovac BiotechsIPV

Sequential Vaccination of Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabin Strains From Different Manufacturers

Start: May 2024Est. completion: Dec 2024200 patients

Phase 4Completed

NCT05432141 Sinovac BiotechsIPV vaccine /DTaP vaccine

A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants

Start: Jun 2022Est. completion: Dec 20223,200 patients

Phase 4Completed

NCT04448132 AJ VaccinesIPV-Al

Evaluation of Persistence of Immunity in 4-year-old Children Previously Immunised With IPV-Al AJV (Picovax®)

Start: Nov 2020Est. completion: May 2021163 patients

Phase 4Completed

NCT02005536 SanofiIMOVAX POLIO®: Inactive Poliovirus Vaccine

Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan

Start: Dec 2013Est. completion: Oct 201460 patients

Phase 4Completed

NCT01094171 GSKPoliorix TM

Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia

Start: Dec 2010Est. completion: Oct 2012400 patients

Phase 4Completed

NCT01244464 SanofiIMOVAX Polio™-Inactivated types 1, 2, and 3 poliovirus D vaccine

A Study of the Safety of IMOVAX Polio™ in China

Start: Nov 2010Est. completion: Dec 2011800 patients

Phase 4Completed

NCT00611559 GSKInfanrix™ penta

Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children

Start: Feb 2008Est. completion: Jun 2008283 patients

Phase 4Completed

NCT00635128 GSKBoostrix-Polio

Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine

Start: Feb 2008Est. completion: Jul 2008415 patients

Phase 4Completed

NCT05850364 Sinovac BiotechSabin Strain Inactivated Poliovirus Vaccine

A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine

Start: May 2023Est. completion: Feb 20251,442 patients

Phase 3Completed

NCT05386810 Sinovac BiotechExperimental vaccine

Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants

Start: Nov 2020Est. completion: Jul 20231,572 patients

Phase 3Completed

NCT04386707 Sinovac BiotechThree doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age

Lot-consistency Clinical Trial of Sabin Strain Inactivated Polio Vaccine

Start: May 2020Est. completion: Oct 20201,300 patients

Phase 3Completed

NCT03822767 Sinovac BiotechsIPV-sIPV-bOPV vaccination schedule

A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a "2+1"Sequential Schedule With bOPV in Infants

Start: Jun 2018Est. completion: Dec 2018240 patients

Phase 3Completed

NCT03822754 Sinovac BiotechsIPV-bOPV-bOPV vaccination schedule

A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in Infants

Start: Jun 2018Est. completion: Dec 2018240 patients

Phase 3Completed

NCT03671616 AJ VaccinesIPV-Al SSI

Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months

Start: May 2018Est. completion: Oct 2018666 patients

Phase 3Completed

NCT03526978 Sinovac BiotechInvestigational sIPV

An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants

Start: Aug 2017Est. completion: Apr 20181,200 patients

Phase 3Completed

NCT03032419 AJ VaccinesIPV-Al SSI

Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months

Start: Feb 2017Est. completion: Mar 20181,002 patients

Phase 3Completed

NCT03025750 AJ VaccinesIPV-Al SSI

Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine in 2, 4, 6 Months of Age

Start: Jan 2017Est. completion: Nov 2017800 patients

Phase 3Completed

NCT02434770 BiocorpBBIBP Bivalent Oral Poliomyelitis Vaccine Lot 1

Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine

Start: Aug 2015Est. completion: Jun 2016750 patients

Phase 3Completed

NCT02096263 GSKInfanrix hexa

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

Start: Apr 2014Est. completion: Nov 2015585 patients

Phase 3Completed

NCT01353703 GSKInfanrix hexa™

Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine

Start: Apr 2012Est. completion: Feb 2013224 patients

Phase 3Completed

NCT01323647 GSKPoliorixTM

Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated Toddlers

Start: Apr 2011Est. completion: Sep 2011957 patients

Phase 3Completed

NCT01309646 GSKInfanrix™-IPV+Hib

Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine

Start: Mar 2011Est. completion: Feb 2012454 patients

Phase 3Completed

NCT01021293 GSKPoliorix™

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vaccine

Start: Nov 2009Est. completion: Jul 20101,101 patients

Phase 3Completed

NCT00920439 GSKPoliorixTM

Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers

Start: Jun 2009Est. completion: Aug 200926 patients

Phase 3Completed

NCT00348387 SanofiPoliomyelitis Vaccine inactivated

Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV

Start: Jun 2006Est. completion: Dec 2008600 patients

Phase 3Completed

NCT00258843 SanofiInactivated Poliomyelitis vaccine

Safety of Imovax Polio in Chinese Infants and Children

Start: Nov 2005Est. completion: Apr 200640 patients

Phase 3Completed

NCT00352963 GSKStudy vaccines: IH+Hib-MenC/NVC; Control: IH+Meningitec

Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).

Start: Sep 2003Est. completion: Jul 2004480 patients

Phase 3Completed

NCT06895486 BiocorpNovel Oral Polio Vaccine Type 1

Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation

Start: Nov 2025Est. completion: Dec 2026675 patients

Phase 2Recruiting

NCT05654467 BiocorpNovel Live Attenuated Type 3 Oral Poliomyelitis Vaccine

Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama

Start: Dec 2023Est. completion: Nov 20251,532 patients

Phase 2Unknown

NCT05644184 BiocorpNovel Live Attenuated Type 1 Oral Poliomyelitis Vaccine

Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh

Start: Mar 2023Est. completion: May 20262,232 patients

Phase 2Recruiting

NCT04693286 Biocorpnovel oral polio type 2 vaccine

Clinical Trial of Novel OPV2 Vaccine

Start: Sep 2020Est. completion: Aug 2021330 patients

Phase 2Completed

NCT00604058 SanofiInactivated Poliomyelitis vaccine

Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly

Start: Jan 2008Est. completion: Dec 2008236 patients

Phase 2Completed

NCT06577298 CanSino BiologicsRecombinant Trivalent Poliomyelitis Vaccine

A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers

Start: Dec 2024Est. completion: Dec 2026480 patients

Phase 1/2Recruiting

NCT06137664 BiocorpNovel oral poliomyelitis vaccine type 1

Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines

Start: Nov 2024Est. completion: Dec 20272,400 patients

Phase 1/2Recruiting

NCT02985320 Sinovac BiotechSingle-dose regimen of high dosage investigational sIPV

Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine

Start: Oct 2016Est. completion: Jun 2017708 patients

Phase 1/2Completed

NCT06101173 CanSino BiologicsRecombinant Trivalent Poliomyelitis Vaccine

A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults

Start: Jan 2024Est. completion: Sep 202472 patients

Phase 1Completed

NCT00937404 GSKPoliorix

Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants

Start: Aug 2009Est. completion: Nov 200925 patients

Phase 1Completed

NCT04989231 Sinovac BiotechInvestigational sIPV

An Immunity Persistence Study of Sabin Inactivated Poliovirus Vaccine(Vero Cell) After Four Doses

Start: Sep 2021Est. completion: Dec 2022450 patients

N/ACompleted

NCT04618783 Sinovac BiotechThree doses of low-dosage investigational sIPV, vaccinated within one-month interval between doses

Cross-neutralization Capacity of Immune Serum From Different Dosage of Sabin Inactivated Poliovirus Vaccine Immunization

Start: Jul 2019Est. completion: Jan 2020250 patients

N/ACompleted

NCT00514033 GSKPoliomyelitis vaccine

A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children

Start: Jul 2007Est. completion: Jul 2011349 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

18 late-stage (Phase 3) programs, potential near-term approvals

6 actively recruiting trials targeting 30,488 patients

8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.